NCT05256225 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05256225
Title	Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Recruitment	Recruiting
Gender	female
Phase	Phase III
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	ovarian clear cell carcinoma endometrial serous adenocarcinoma endometrioid ovary carcinoma ovarian carcinosarcoma uterine carcinosarcoma
Therapies	Carboplatin + Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Carboplatin + Paclitaxel Carboplatin + Paclitaxel Trevatide + trastuzumab and hyaluronidase-oysk injection
Age Groups:	adult \| senior
Covered Countries	USA

Additional content available in CKB BOOST